The Correlation between Proliferative Immunohistochemical Markers and Papillary Thyroid Carcinoma Aggressiveness.


Journal

Medicina (Kaunas, Lithuania)
ISSN: 1648-9144
Titre abrégé: Medicina (Kaunas)
Pays: Switzerland
ID NLM: 9425208

Informations de publication

Date de publication:
04 Jan 2023
Historique:
received: 23 12 2022
accepted: 27 12 2022
entrez: 21 1 2023
pubmed: 22 1 2023
medline: 25 1 2023
Statut: epublish

Résumé

Background and Objectives: Papillary thyroid carcinoma (PTC) is one of the most common malignancies of the endocrine system. In order to improve the ability to predict tumor behavior, several studies have been conducted to search for surrogate prognostic immunohistochemical tumor markers. Objective: To evaluate the correlation between the intensity of different immunohistochemical marker staining in PTC and the risk for extrathyroidal extension and metastases. Materials and Methods: The study comprised patients who underwent hemi- or total thyroidectomy. Thyroid tissues were immunohistochemically stained for different tumor proliferative markers: Minichromosome maintenance proteins 2 (MCM2), Ki-67 labeling index, E-Cadherin, Neuropilin-1 and Metallothionein. The correlation between the intensity of each marker staining and the final diagnosis (benign neoplasm and PTC) and the correlation between the intensity of each staining and tumor extrathyroidal extension and metastases were evaluated. Results: The study included 66 patients. Staining for Metallothionein, E-Cadherin and MCM2 significantly differed between benign neoplasm (n = 22) and thyroid-confined PTC (n = 21) (p = 0.002, 0.004 and 0.005, respectively), between benign neoplasm and PTC with extrathyroidal extension (n = 11) (p = 0.001, 0.006 and 0.01, respectively), and between benign neoplasm and PTC with metastases (n = 12) (p = 0.01, <0.001 and 0.037, respectively). No staining correlated with extrathyroidal extension. The intensity of E-Cadherin staining was significantly lower in PTC with metastases than thyroid confined PTC and PTC with extrathyroidal extension (p = 0.028 and 0.021, respectively). Conclusions: Immunohistochemical staining for Metallothionein, E-Cadherin and MCM2 significantly distinguished between benign thyroid tumor and PTC. E-Cadherin staining significantly and inversely correlated with the presence of metastases.

Identifiants

pubmed: 36676734
pii: medicina59010110
doi: 10.3390/medicina59010110
pmc: PMC9862399
pii:
doi:

Substances chimiques

Cadherins 0
Biomarkers, Tumor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Open Access Maced J Med Sci. 2017 Mar 22;5(2):155-159
pubmed: 28507620
World J Surg. 2010 Dec;34(12):3015-21
pubmed: 20703465
J Surg Oncol. 2001 Mar;76(3):176-80
pubmed: 11276021
Cancer Lett. 2013 Jul 10;335(1):232-41
pubmed: 23435375
Ann Endocrinol (Paris). 2019 Nov;80(5-6):324-328
pubmed: 31703800
Int J Clin Exp Pathol. 2013 Dec 15;7(1):322-30
pubmed: 24427353
Diagn Pathol. 2013 Sep 20;8:155
pubmed: 24053763
Mod Pathol. 2011 Apr;24 Suppl 2:S34-43
pubmed: 21455199
Thyroid Res. 2012 Dec 28;5(1):26
pubmed: 23273222
Exp Mol Pathol. 2010 Feb;88(1):138-42
pubmed: 19818763
Clin Chim Acta. 2019 Apr;491:39-45
pubmed: 30653951
Medicine (Baltimore). 2019 Jul;98(30):e16187
pubmed: 31348230
Onco Targets Ther. 2018 Aug 20;11:5025-5034
pubmed: 30174440
Diagn Cytopathol. 2017 Aug;45(8):714-730
pubmed: 28262004
Adv Anat Pathol. 2016 Jul;23(4):244-71
pubmed: 27145091
Endocr J. 2021 Aug 28;68(8):871-880
pubmed: 33980775
Front Oncol. 2015 Jun 03;5:125
pubmed: 26090340
Cancer Cell Int. 2003 Oct 14;3(1):17
pubmed: 14613514
Adv Anat Pathol. 2011 Jan;18(1):90-7
pubmed: 21169742
Histopathology. 2006 Jun;48(7):801-7
pubmed: 16722928
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Ann Diagn Pathol. 2008 Oct;12(5):340-3
pubmed: 18774496

Auteurs

Mohammad Sheikh-Ahmad (M)

Institute of Endocrinology, Bnai Zion Medical Center, 47 Golomb St., Haifa 31048, Israel.

Yara Shalata (Y)

Institute of Endocrinology, Bnai Zion Medical Center, 47 Golomb St., Haifa 31048, Israel.

Jacob Bejar (J)

Department of Pathology, Bnai Zion Medical Center, 47 Golomb St., Haifa 31048, Israel.

Hila Kreizman Shefer (H)

Department of Pathology, Bnai Zion Medical Center, 47 Golomb St., Haifa 31048, Israel.

Majd F Sirhan (MF)

Department of Pathology, Bnai Zion Medical Center, 47 Golomb St., Haifa 31048, Israel.

Monica Laniado (M)

Department of Surgery, Bnai Zion Medical Center, 47 Golomb St., Haifa 31048, Israel.

Ibrahim Matter (I)

Department of Surgery, Bnai Zion Medical Center, 47 Golomb St., Haifa 31048, Israel.

Abed Agbarya (A)

Department of Oncology, Bnai Zion Medical Center, 47 Golomb St., Haifa 31048, Israel.

Maria Reut (M)

Institute of Endocrinology, Bnai Zion Medical Center, 47 Golomb St., Haifa 31048, Israel.

Ekaterina Yovanovich (E)

Institute of Endocrinology, Bnai Zion Medical Center, 47 Golomb St., Haifa 31048, Israel.

Leonard Saiegh (L)

Institute of Endocrinology, Bnai Zion Medical Center, 47 Golomb St., Haifa 31048, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH